{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"13","value":"6"}]}],"title":"Day 100"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"24","value":"15"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"description":"Percentage of participants who died for BMT-related reasons.","dispersionType":"95% Confidence Interval","groups":[{"description":"Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.","id":"OG000","title":"Bone Marrow Transplant"}],"paramType":"NUMBER","populationDescription":"The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. NRM data was not collected on the remaining 25 participants.","reportingStatus":"POSTED","timeFrame":"Day 100, 2 years","title":"Non-relapse Mortality","type":"SECONDARY","unitOfMeasure":"percentage of participants"}